ARGX · ARGX Q2 FY2026 earnings call record财报电话会记录

“Our future FCRN molecules, ARGX-213 and ARGX-124, as well as our IgA sweeper, ARGX-121, are progressing towards late-stage development”

“ARGX-118, ARGX-125, and TSP-101, now in phase I, each represent new pipeline and product opportunities.”

“Product net sales for the second quarter were $1.5 billion, representing 60% year-over-year growth and 17% quarter-over-quarter growth.”

“By region, product net sales were $1.3 billion in the U.S., $102 million in Japan, $136 million across the rest of the world, and $5 million related to product supply to Zai Lab in China.”

“In Japan, quarter-over-quarter net product sales growth is 55% or $35 million.”

“We had shared data specifically from phase I and with the profile that showed that ARGX-121 reduces IgA by about 90% within a matter of days, and that reduction is maintained all the way out till day 28 with one single dose.”

“On the pipeline, could you just provide some updated thoughts on how you're thinking about advancement between your next-gen FcRn candidates ARGX-213 and ARGX-124?”

“Our next-generation molecules, 213 and 124 that you referred to, 213 is we call it phase III-ready, and 124, we're in phase I at the moment, and by the end of the year, we'll be in a position to move it into late-stage clinical development.”

“If so, how should we think about the progression of the launch in that segment going forward?”

“Just to confirm, auto-injector is on target or on schedule for 2027 launch.”

“With the strength of our balance sheet, and our continued profitability, we can now widen the lens and also look at biotech companies that are pursuing, but we use the same bar for those business development opportunities as we do for our internal pipeline.”

“We hold the bar high, but I can tell you when we find those opportunities where we can have an impact for patients, we will leverage the flexibility of the balance sheet to be able to go after them and continue to build our pipeline.”